Artal Group’s AMAG Pharmaceuticals AMAG Stock Holding History

Artal Group’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-300,000	Closed	-$7.35M	–	106
2016 Q3	$7.35M	Buy	+300,000	New	+$7.5M	0.15%	41

Other funds holding AMAG

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Artal Group's AMAG Position: Q4 2016 in Review

Artal Group sold out of AMAG Pharmaceuticals (AMAG) in Q4 2016, closing a stake of 300,000 shares — an estimated $7.35M sold.

Artal Group first reported a position in AMAG in Q3 2016 and held it in 1 quarter. The position peaked at $7.35M in Q3 2016. 206 funds tracked by Wall St. Rank hold AMAG as of Q4 2016.

Artal Group reported no remaining AMAG Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Artal Group sold 300,000 AMAG Pharmaceuticals shares in Q4 2016, an estimated $7.35M.
Artal Group first reported a position in AMAG Pharmaceuticals in Q3 2016 and held it in 1 quarter.
Artal Group's AMAG Pharmaceuticals position peaked at $7.35M in Q3 2016.
206 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2016.

Based on Artal Group's 13F filing for Q4 2016, filed 14 Feb 2017.